Veru Inc. (VERU)

Price$3.40

Value ScoreA

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)29.17%

Price vs S&P 500 (4W)51.80%

VGM Score66.12

Market Capitalization$36.11M

All Metrics

Book Value / Share (Quarterly)$2.17

P/TBV (Annual)3.48x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-34.92%

Cash Flow / Share (Quarterly)$-1.62

Price vs S&P 500 (YTD)50.72%

Gross Margin (TTM)34.66%

Net Profit Margin (TTM)-223.86%

EPS (TTM)$-0.78

10-Day Avg Trading Volume10.43M

EPS Excl Extra (TTM)$-0.78

Revenue Growth (5Y)-11.89%

EPS (Annual)$-2.80

ROI (Annual)-89.59%

Gross Margin (Annual)34.67%

Net Profit Margin (5Y Avg)-208.17%

Cash / Share (Quarterly)$1.92

Revenue Growth QoQ (YoY)72.36%

ROA (Last FY)-62.57%

Revenue Growth TTM (YoY)3.62%

EBITD / Share (TTM)$-1.04

ROE (5Y Avg)-150.44%

Operating Margin (TTM)-218.61%

Cash Flow / Share (Annual)$-2.05

P/B Ratio1.04x

P/B Ratio (Quarterly)1.02x

Net Income / Employee (Annual)$-1,890,100

EV / Revenue (TTM)0.50x

Net Interest Coverage (TTM)-42.80x

ROA (TTM)-37.76%

EV / EBITDA (TTM)0.65x

EPS Incl Extra (Annual)$-2.80

Current Ratio (Annual)2.43x

Quick Ratio (Quarterly)5.71x

3-Month Avg Trading Volume1.21M

52-Week Price Return-43.62%

Revenue / Employee (TTM)$844,300

Tangible BV / Share (Quarterly)$2.21

P/S Ratio (Annual)2.14x

Asset Turnover (Annual)0.28x

52-Week High$7.40

Operating Margin (5Y Avg)-203.80%

EPS Excl Extra (Annual)$-2.80

CapEx CAGR (5Y)-60.34%

Tangible BV CAGR (5Y)21.71%

26-Week Price Return37.10%

Quick Ratio (Annual)2.35x

13-Week Price Return32.81%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.19x

Enterprise Value$8.52M

Revenue / Share Growth (5Y)20.05%

Asset Turnover (TTM)0.24x

Book Value / Share Growth (5Y)23.78%

Revenue / Employee (Annual)$844,300

Inventory Turnover (Annual)2.04x

Pretax Margin (Annual)-219.56%

Cash / Share (Annual)$1.25

3-Month Return Std Dev182.94%

Gross Margin (5Y Avg)61.87%

Net Income / Employee (TTM)$-697,700

ROE (Last FY)-116.97%

Net Interest Coverage (Annual)-42.83x

EPS Basic Excl Extra (Annual)$-2.80

P/FCF (TTM)9.09x

Receivables Turnover (TTM)3.99x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.78

Receivables Turnover (Annual)3.99x

ROI (TTM)-52.86%

P/S Ratio (TTM)2.14x

Pretax Margin (5Y Avg)-208.12%

Revenue / Share (Annual)$1.25

Tangible BV / Share (Annual)$2.21

Price vs S&P 500 (52W)-67.98%

Year-to-Date Return58.88%

5-Day Price Return42.86%

EPS Normalized (Annual)$-2.80

ROA (5Y Avg)-68.61%

Net Profit Margin (Annual)-223.86%

Month-to-Date Return43.46%

Cash Flow / Share (TTM)$-1.49

EBITD / Share (Annual)$-2.72

Operating Margin (Annual)-218.61%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-107.33%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.78

P/TBV (Quarterly)3.48x

P/B Ratio (Annual)3.04x

Inventory Turnover (TTM)2.04x

Pretax Margin (TTM)-219.56%

Book Value / Share (Annual)$1.25

Price vs S&P 500 (13W)24.56%

Beta-1.20x

P/FCF (Annual)42.49x

Revenue / Share (TTM)$1.15

ROE (TTM)-52.86%

52-Week Low$2.05

vGradeA

gGradeC

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q2 26-0.12est. -0.29

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.25

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
VERUVeru Inc.	A	C	B	$3.40
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Veru is a late-stage biopharmaceutical developing therapies for cardiometabolic and inflammatory diseases. Enobosarm, a selective androgen receptor modulator, is in Phase 2b development for obesity to enhance fat loss selectivity when combined with GLP-1 RA drugs. Sabizabulin, an oral microtubule disruptor, is advancing to Phase 2 trials for atherosclerotic cardiovascular disease to reduce inflammation and high-sensitivity CRP levels.